Nasal anti-CD3 mAb-mediated Treg induction for traumatic brain injury

Nasal delivery of an antibody that engages the transmembrane protein CD3 could help treat traumatic brain injury by promoting the activity and migration of IL-10-producing Treg cells to the brain, thus decreasing microglial inflammation while increasing phagocytosis of apoptotic neurons by microglia.

In a mouse model of traumatic brain injury induced by mechanical stimulation, nasal administration of an anti-CD3 antibody tool compound previously shown to induce Tregs decreased brain parenchymal lesion volume, neuronal cell death, microgliosis, edema, serum levels of biomarkers for traumatic brain injury, and anxiety behaviors as assessed by open field test compared with an isotype control; the antibody also increased motor function and coordination as assessed by rotarod test, spatial memory as assessed by Morris water maze test, blood-brain barrier integrity, and serum anti-inflammatory cytokine levels. ...